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Abstract

Seven novel, amphiphilic AApeptides were prepared. Two cationic, lipo-αAApeptides, NA-75 and NA-77 were found to possess potent antimicrobial activity
against Gram-positive bacteria, with almost no hemolytic activity. In addition to NA-75
and 77, four amphiphilic, γ-AApeptides, NA-133, 135, 137, and 139, and one anionic
lipo-α-AApeptide, NA-81, were prepared for molecular self-assembly studies, with
several interesting nanostructures observed by TEM. Mineralization of calcium carbonate
from gaseous CO2 and Ca2+ in the presence of the 7 AApeptide amphiphiles was also
observed by optical microscopy. Several AApeptides were found to be able to influence
CaCO3 crystal morphology. Another α-AApeptide, NA-63, was synthesized by a novel,
alternative method, which has several potential advantages over the previous synthesis
methods.
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Chapter 1:
Design and Synthesis of Antimicrobial α-AApeptides

1.1 Introduction
1.1.1 Overview
Peptidomimetics are a diverse class of synthetic compounds designed to mimic
the structure and/or function of peptides, but with modified backbones. Unlike natural
peptides, peptidomimetics possess backbones which are not based solely on α-L-amino
acids. Peptidomimetics are typically designed by modifying peptides, or through mimicry
of peptide secondary structure. Peptides are highly involved in important biological
processes and are therefore of great pharmaceutical interest.1,2
Unfortunately, natural peptides have several disadvantages which may limit their
therapeutic application – particularly their susceptibility to proteolysis.3,4 The
development of peptidomimetics, including the newly-developed AApeptides, which are
the subject of this research, is an attempt to overcome some of the disadvantages of
peptides while retaining their functionality, as well as exploiting any potential advantages
offered by the non-natural peptide mimics. Herein we report the novel synthesis of
several AApeptides, and subsequent investigation of their potential utility. AApeptides
are a new class of peptide mimics developed by our laboratory, derived from the alphachiral PNA (peptide-nucleic acid) backbone, shown in Figure 4.3,4 AApeptides are
oligomers of N-acylated-N-aminoethyl amino acids, first reported by members of my
1

research group in 2011.3,4 Our laboratory reported the novel synthesis of both αAApeptides and γ-AApeptides, which are very similar, but differ in the positioning of
side-chains along the backbone.3,4

Figure 1: α-Peptides, α-AApeptides, and γ-AApeptides. Representative structure of 12-residue α-peptide
(top), 6-block α-AApeptide (middle), and 6-block γ-AApeptide (bottom). AApeptides have the same
number of side-chains and amide bonds as α-peptides of the same length.

Peptides are of significant biomedical interest, owing to their involvement in
practically every vital biological process.2 Some functions of peptides that are interesting
include disruption of protein-protein interaction, inhibition or modulation of enzyme
activity, and (as in this research) antimicrobial activity.1 The ability to exploit peptides as
potential pharmaceuticals or compounds of other biological interest is highly desirable in
bioorganic and chemical biology. Peptidomimetics designed to imitate the structure of
interesting peptides may be able to express the functionality of such peptides, or even
improve upon them.3-5

2

A wide variety of peptidomimetics have been reported, mainly differing in their
backbone structures. Examples include peptoids,6 β-peptides,7-9 α/β-peptides,10,11 γ- and
δ- peptides,12-14 oligoureas,15,16 polyamides,17 sugar-based peptides,18,19 azapeptides, αaminoxy-peptides,20 and phenylene ethynylenes.21 Just as there are a vast number of
possible natural peptides, depending on the sequence and number of amino acids, each
type of peptidomimetic may represent a vast number of possible compounds, potentially
an entire library of compounds whose properties can be further investigated. Therefore,
the development of novel peptidomimetic backbones with a high potential for
diversification, and straightforward, low-cost synthesis and tunability is greatly
needed.10,22

1.1.2 Natural peptides
Natural α-peptides represent a vast number of unique compounds, many with
pharmaceutically and biologically interesting functions, which are difficult to exploit as
pharmaceuticals for several reasons. Natural peptides are susceptible to proteolysis –
degradation by proteolytic enzymes. This gives them poor in vivo stability, which limits
their use as potential drug candidates. Natural peptides can also be immunogenic,
potentially triggering immune response. Such immune responses may further impact the
bioavailability of the peptide, or an autoimmune response could be provoked.23
Nevertheless, many peptides might be quite useful if not for such caveats.
Because peptides are made of chiral, L-α-amino acids, their primary structure is
not the only factor in determining their functionality.24 Peptides, even relatively short
ones, adopt a variety of secondary structures, called foldamers, such as α-helices, β-
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sheets, etc.24 These structural motifs are often very important to the peptide's function,
especially peptide aptamers. The diverse biological functions of peptides include such
physiologically important functions as neurotransmitters, neuromodulators, hormones, as
well as many others.1,2

1.1.3 Peptidomimetics
Peptidomimetics have recently begun to be recognized as a potential strategy to
modify the structures of interesting peptides in order to make them potentially better as
therapeutics or otherwise biomedically useful, especially by improving their biostability
and bioavailability. Some peptidomimetics that have been reported are peptoids,6 βpeptides,7-9 α/β-peptides,10,11 γ- and δ- peptides,12-14 oligoureas,15,16 polyamides,17 sugarbased peptides,18,19 azapeptides, α-aminoxy-peptides,20 and phenylene ethynylenes.21 Damino acids may also be considered as falling into this category, since D-amino acids
only occur rarely in nature.25-29 Peptidomimetics are often stable to proteolysis, and are
believed to possess reduced immunogenicity and improved bioavailability compared to
natural peptides.3,4 Certain peptidomimetics have a high potential for diversification, due
to the synthetic methods used to make them. Whereas natural peptides are generally
limited to the classic 20 natural amino acid side-chains, peptidomimetics may be able to
incorporate un-natural side-chains, allowing for greater structural diversity.30,31 The
development of novel backbones with new and unique properties is still needed in order
to discover new molecules of interest to biomedical and chemical biology.22
Covalently modified peptides occur in nature, often resulting from posttranslational modifications. These include lipopeptides, glycopeptides, N- and O-

4

α-peptide

α-AApeptide

γ-AApeptide

β3-peptide
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Figure 2: α-Peptides, α-AApeptides, γ-AApeptides, peptoids,6 and β-peptides7-9.

acylation, etc.32 Likewise, peptidomimetics may also be further derivatized by chemical
modification. Such possible derivatization strategies for these include cyclization,
lipidation, oligosaccharide conjugation, acylation, etc.
As mentioned previously, the primary structure of peptides is not the only factor
in their activity, their 3D structure is important too. The spatial orientation of side-chain
groups may be equally as important as the composition of the different side-chains
themselves.3 Therefore, it is useful for peptidomimetics to be able to display
conformational characteristics similar to peptide secondary structure. For example, a
helical domain of the tumor suppressor protein p53 binds to MDM2.3,4 Disruption of this
protein-protein interaction is desirable to anti-cancer research, but challenging to achieve
with peptidomimetics, due to the importance of 3D structural orientation of the
interacting residues.3,4 Although the development of peptidomimetics with wellcontrolled secondary structure tends not to be straightforward, peptidomimetics which
5

demonstrate such highly specific interactions have been reported, including
AApeptides.3,4
Peptidomimetics may be useful for disruption of protein-protein interactions,
inhibition or modulation of enzyme activity, and (as in this project) antimicrobial
activity.33 They may also be useful for the investigation of the importance of structural
characteristics to peptide activity/behavior.34-36 Peptidomimetics can be made to mimic
peptide aptamers, with highly specific interactions, or to mimic broad, global features of
peptides, such as overall or regional cationic/anionic charge, hydrophobicity, etc.6,37
Peptidomimetics, including AApeptides, can also be made to mimic short sections of
larger peptides, to act as aptamers/inhibitors with high specificity and binding affinity.
Some of the functions of short peptides that we are interested in mimicking in this
research are antimicrobial activity, self-assembly to form nanostructures, and the ability
to influence mineral crystallization. These functions appear to be more dependent upon
the overall characteristics of the peptide/peptidomimetic, rather than upon the highly
specific interactions of aptamers.36,38-40

1.1.4 AApeptides
As previously mentioned, there are two types of AApeptides, which vary in the
position of chiral substitution on the backbone. The two types are shown in Figure 3.
Both types of AApeptides were first reported by my research group in 2011.3,4 They are
non-natural peptide oligomers based upon chiral PNA (peptide-nucleic acid) backbone.3,4
In early work, both α- and γ-AApeptides were found to be highly resistant to enzymatic
hydrolysis by chymotrypsin, trypsin, and pronase.3,4 AApeptides are highly diversifiable,
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due to the ability to incorporate a wide variety of side-chains by N-acylation, not limited
only to the typical amino acid side-chains.3,4,41

α-AApeptide

γ-AApeptide

Figure 3: α- and γ-AApeptides.

Each repeating unit is analogous to a dipeptide, possessing two side-chains, and
the same backbone length. This means that longer AApeptides will have the same
number of side-chains as natural peptides of the same length. They will also have the
same number of backbone amide bonds as natural α-peptides for a given chain length.
These structural similarities, along with the improved resistance to proteolysis, and
straightforward diversifiability and tunability, should make AApeptides very good
candidates for development of new peptide-based biomimetic compounds, such as
chemical probes, pharmaceuticals, etc. 3,4,42,43
AApeptides have only half the number of chiral centers per side chain as a corresponding
α-peptide. One half of the backbone amides are tertiary amides, which can be oriented
either cis or trans, and no longer possess the same H-bonding characteristics as the
secondary amide of an α-peptide. This means that the secondary structure is expected to
be different than that of α-peptides. The structural properties of AApeptides are still not
fully explored yet; further study should improve the ability to predict and control
AApeptide secondary structural characteristics.

7

Figure 4: PNA backbone, α- and γ-AApeptide backbones. Representative structure of PNA backbone
(top), in which the "side-chains" are nucleobases instead of typical amino acid side-chains, α-AApeptide
(middle), and γ-AApeptide (bottom).

Since the introduction of AApeptides, there have been multiple strategies used in
their synthesis. The first was by synthesizing "dipeptidomimetic" building blocks, each
with two side-chain groups (protected as necessary), an Fmoc-protected amino group,
and an acid group. These were then linked to other building blocks by solid-phase
synthesis, in much the same way as is done for synthetic α-peptides. This method can be
used to make both α- and γ-AApeptides, from their corresponding building blocks
units.3,4,31
Another method was developed and is reported here for the first time, using
building blocks with alloc-protection of the terminal nitrogen, and Fmoc-protection of the
secondary amine, rather than acylation to introduce another side chain. See Figure 12 for
an illustration of this strategy. This would allow the N-acyl side chain to be added during
solid-phase synthesis, following deprotection to the secondary amine, by acylation using
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Figure 5: Example of an α-AApeptide building block.

any compatible carboxylic acid or acyl chloride. De-alloc-protection can be performed
during solid phase synthesis using tetrakis(triphenylphosphine) palladium (0) as a
catalyst.44 This method could allow a greater variety of possible sequences to be made
from a given number of building blocks, compared to using the previously established
method, since only one of the two side-chains of each building block would be predetermined. This method has been used to make α-AApeptides, as reported in this
research, and a very similar approach was used by our laboratory to make γ-AApeptides
by a combinatorial approach.44
Notably, it is possible to synthesize γ-AApeptides by a sub-monomer strategy,
circumventing building block synthesis, and preparing the sequences entirely on solid
phase, from relatively simpler units. This is reported by our laboratory previously, but
falls outside the scope of this manuscript.43
AApeptides have a high potential for diversification, especially at the tertiary
amide. Because the acylation is done using any of a wide variety of commercially

9

α-AApeptide building block

γ-AApeptide building block

Alloc/Fmoc α-AApeptide building block

Figure 6: Representative AApeptide building blocks.

available carboxylic acid or acyl chloride derivatives, the possibilities for half the sidechains are practically limitless. The other side chain typically comes from a natural αpeptide, but other non-natural α-peptides could be incorporated as well, such as D-amino
acids, or amino acids with non-natural side-chains, etc.3,4
The first α-AA peptides were reported by our laboratory in 2011.3,4 They were
found to selectively inhibit protein-protein interaction between p53 and MDM2. They
showed high selectivity, and also significant stability to proteolysis.3 Soon after, our lab
reported γ-AA peptides, which were also able to disrupt p53/MDM2 interaction, with
similarly favorable stability toward enzymatic degradation.4 This initial work provides
evidence for the potential applicability of AApeptides as non-natural oligomers with
potent bioactivity, high specificity, and stability.3,4
Although the continued investigation of AApeptide aptamers is important, the
focus of this research was on compounds whose overall structural characteristics are
10

more important to their function than their precise molecular structure. The common
feature of the peptidomimetics that were synthesized over the course of this research is
that they are amphiphilic, with part of the molecule hydrophilic due to charge in aqueous
solution, and part of the molecule hydrophobic. My research has focused on the
development of novel synthetic methods to make both α-and γ-AApeptides. Several αAApeptides were made to explore potential applications of AApeptides as potential novel
antimicrobial agents, inspired by AMPs.

1.1.5 Antimicrobial peptides
Antimicrobial peptides (AMPs), also called host defense peptides (HDPs), are
found in nearly all living organisms, including humans, and play an important role in the
innate immune system, providing defense against a variety of infections.45 Generally,
they are short, cationic, amphiphilic peptides, often adopting helical conformations.45,46
Cationicity is due to a large number of basic residues, such as lysine, histidine,
tryptophan, or arginine, which are protonated under physiological pH. Hydrophobicity is
typically afforded by hydrophobic residues, such as phenylalanine, valine, leucine, and
isoleucine. Magainin is a typical example of a helical AMP, while indolicidin is an
example of an AMP that adopts an extended structure.47 There is a hope that AMPs could
lead to a new type of broad-range antibiotic, which provides protection from a variety of
pathogenic bacteria, without causing resistance to develop.35,47-49
AMPs have come to be regarded as a potential source of antibiotics for future use,
serving as drug leads to guide the development of new types of antibiotics.35,49 Current
conventional antibiotics have become increasingly ineffective over the years, as many
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microbes have developed resistance to them. This problem has very serious global health
consequences. It is hoped that AMP-inspired antibiotics could circumvent bacterial
resistance, since, unlike most conventional antibiotics, which act through highly specific
interactions with bacterial enzymes, proteins, etc., AMPs are believed to act through
more general interactions with the bacterial membrane.49 They have low susceptibility to
the development of antibiotic resistance, most importantly.49,50
AMPs' overall cationic charge and amphipathicity allow them to cause disruption
of bacterial membranes, by causing membrane thinning, poration, and leakage. The exact
mechanism is not precisely known, but it is believed that charge interactions between the
cationic AMPs and the anionic bacterial cell membranes cause the AMPs to accumulate
on the cells, where hydrophobic interactions with membrane phospholipids cause the
AMP to insert into the membrane.49 This results in a loss of membrane integrity, and
microbial death.49 Since mammalian cell membranes are zwitterionic, there is no
electrostatic attraction to the cationic AMPs.51 This allows AMPs to have high selectivity
toward pathogens, without damaging mammalian cells.51 Because of the membranedisruption mechanism, acquiring resistance to AMPs is more difficult compared to
conventional antibiotics.48 Indeed, AMPs have been a part of the innate immune defense
of organisms for millions of years, yet are still effective.
Conventional antibiotics typically act by highly specific interactions with some
bacterial enzyme or protein. This leads to antimicrobial resistance by several
mechanisms, including mutations of enzymes so that they are no longer inhibited by the
antibiotic, but retain their functionality.48 Such mechanisms allow bacteria to very
quickly develop resistance to new antibiotics. Due to their unique mechanism of action,
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AMPs are able to provide protection from a variety of pathogenic bacteria, acting as
broad-range antibiotics, without propensity for inducing resistance.48
AMPs have many of the same potential drawbacks as many other biomedically
interesting peptides: they are intrinsically unstable to degradation by proteolysis, and they
may also be immunogenic.33 Also, they typically only have moderate antimicrobial
activities, leaving more potent activity to be desired.52 Their structure is relatively simple,
and their overall characteristics are more important to their function than the specific
sequence of amino acids, which makes development of peptidomimetic analogues
simpler and more straightforward, compared to peptide aptamers, which tend to require
highly specific 3-dimensional positioning. Although many AMPs possess a helical
structure, it is believed that this may not be necessary to their antimicrobial activity.40,53,54
Rather, helical AMPs may have higher hemolytic activity compared to those with
extended or random-coil structure.38,49
Because AMPs have activity against a broad range of antimicrobial organisms, it
is hoped that peptidomimetic analogues would have a similar broad-range of activity,
leading to new antibiotics for potential therapeutic use. Therefore, a few types of
peptidomimetic analogues of AMPs have been reported, such as β-peptides, arylamides,
and peptoids.31
The addition of saturated fatty acid tails to AMPs has been shown to greatly
improve the bactericidal activity against both Gram-positive and Gram-negative
strains.55-57 Reports of lipidated peptidomimetics are rare,35 but short peptoid AMP
mimetics were also shown to bear improved selectivity and retained antimicrobial
activity when alkylated with 10-13 carbon lipids. Polymyxin B and Daptomycin are two
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antibiotics, which are lipidated peptides, whose fatty acid tails are integral to their
antibacterial activity.
1.1.6 Design and synthetic strategy of α-AApeptides
In 2011, the development of unlipidated α- and γ-AApeptides with broadspectrum antimicrobial activity and low hemolytic activity was reported by others in my
group.30,31 Following this, we began to develop lipidated AApeptides to further
investigate their activity and properties, and with the hypothesis that the addition of a
lipid tail to the previous motif of hydrophobic/cationic side-chains might improve either
the activity or the selectivity.30 I synthesized the lipo-α-AApeptides shown in Figure 7 for
study. Two sequences, NA-75 and 77, were synthesized on solid support, via the standard
α-AApeptide building block method, described in detail in Section 1.2.3 of this chapter.31

Figure 7: NA-75 and 77.
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The synthesized AApeptides then underwent testing to determine their
antimicrobial activity against a series of interesting/pathogenic microbes, including
strains with resistance to conventional antibiotics. Hemolysis testing was also done to
assess the selectivity against bacterial/fungal cells vs mammalian cells. The development
and activity of NA-75 and NA-77 have been reported in a previously published work,31
as well as this manuscript. Lipo-α-AApeptides NA-75 and 77, inspired by AMPs, are
similarly short, cationic, amphiphilic oligomers, with cationicity provided by amino sidechains from the lysine residue, and hydrophobicity provided by the hydrophobic N-acyl
side-chains and an aliphatic palmitoyl tail added to the terminal N. An overview of the
synthetic scheme is given in Figure 11.
To explore alternative synthesis methods, another sequence, NA-63, was made,
using alloc/Fmoc protected building blocks, as shown in Figure 12. As a model, a Phebased alloc/Fmoc α-AApeptide building block was prepared, and a tri-block sequence
with hydrocinnamic acid side-chains added during solid phase synthesis was prepared.
This is the first report of an α-AApeptide made by this method.

Figure 8: NA-63.

1.2 Experimental
15

1.2.1 α-AApeptide building block synthesis
The previously reported 3 procedure for the synthesis of a representative αAApeptide building block (lys/hydrocinnamic acid) is shown below:
Fmoc-Lys (Boc)-OH was benzylated overnight at room temperature in DMF using 5 eq
benzyl bromide and 5 eq solid sodium bicarbonate. After purification, Fmoc protection
was removed from the benzylated product using 2:1 ratio of acetonitrile:diethylamine.
This was followed by reductive amination at 0° C using 1 eq Fmoc-glycine-aldehyde and
1.7 eq sodium cyanoborohydride in methanol. After purification of the secondary amine,
it was subjected to acid coupling overnight at room temperature with hydrocinnamic acid
using 5 eq DhbtOH (3-hydroxy-1,2,3-benzotriazin-4(3H)-one) and 5 eq DIC (N, N’Diisopropylcarbodiimide) as activation agents. The final step was hydrogenation, which
was carried out in the presence of H2 gas and 20% palladium on activated carbon as
catalyst in ethanol. The other building block, shown in Figure 9, was prepared similarly,
but by acylating the secondary amine with 4-methylvaleric acid instead.

Figure 9: α-AApeptide building blocks. The building blocks for NA-75 (left), and NA-77 (right).
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1.2.2 Fmoc/alloc α-AApeptide building block synthesis
Alloc-protected glycinealdehyde, prepared previously, was reductively aminated
at 0 °C using 1 eq phenylalanine t-butyl ester and 1.7 eq NaCNBH3 in methanol. After
purification of the secondary amine, it was Fmoc-protected using 2 eq Fmoc-Cl,
overnight, in a mixture of 1:2 CH2Cl2: saturated NaHCO3 in water.58 The t-butyl ester
was deprotected using 20% TFA in CH2Cl2, giving the final building block.

Figure 10: Phenylalanine-based alloc/Fmoc-α-AApeptide building block.

1.2.3 Solid phase synthesis of NA-75 and 77
Lipidated α-AApeptides were synthesized on Rink amide resin in peptide synthesis
vessels on a Burrell wrist-action shaker following the standard Fmoc chemistry solid
phase peptide synthesis protocol using the previously (Section 1.2.1) synthesized αAApeptide building blocks.47,49,59 Each coupling cycle comprised of Fmoc deprotection
using 20% piperidine in DMF, and 8 h coupling of 1.5 eq α-AApeptide building blocks
onto resin using 4 eq DIC (diisopropylcarbodiimide) / DhbtOH (3-4-Dihydro-3-hydroxy4-oxo-1-2-3-benzotriazine) in DMF. Lipidation was achieved on resin by capping the Nterminus of the final α-AApeptide building block using palmitic acid. The solid support
was then transferred into a 4 mL vial and the lipidated α-AApeptides were cleaved from
resin by 50:48:2 TFA/CH2Cl2 /triisopropylsilane overnight.31
17

Figure 11: Synthetic scheme of NA-75.
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Figure 12: Synthetic scheme of NA-63.

1.2.4 Solid phase synthesis of NA-63
NA-63 was synthesized on Rink amide resin in a peptide synthesis vessel, on a
Burrell wrist-action shaker. Alloc/Fmoc building blocks (prepared in Section 1.2.2 and
shown in Figure 10) were added to the resin, by 8 h coupling of 1.5 eq building block
using 4 eq DIC (diisopropylcarbodiimide) and 4 eq DhbtOH (3-4-Dihydro-3-hydroxy-4oxo-1-2-3-benzotriazine) in DMF. Then, Fmoc protection was removed by 20%
piperidine in DMF, and hydrocinnamic acid (2 eq) was coupled to the secondary amine,
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using 4 eq DIC (diisopropylcarbodiimide) / DhbtOH (3-4-Dihydro-3-hydroxy-4-oxo-1-23-benzotriazine) in DMF. Alloc protection was removed using 20mg
tetrakis(triphenylphosphine)palladium (0), and 100μL phenylsilane. Two more building
blocks added similarly. The third building block was capped using acetic
anhydride/pyridine, to acetlyate the N-terminus. The solid support was then transferred to
a 4 mL vial and the α-AApeptide was cleaved from the resin by 74:24:2 TFA/CH2Cl2
/triisopropylsilane for 2 hours. A synthetic scheme of this synthesis is given in Figure 12,
on the previous page.

1.2.5 Purification and characterization
Following cleavage of α-AApeptides NA-63, 75, and 77 from solid support, the
solvent was evaporated by rotary evaporation and the residues were analyzed and purified
on an analytical (1 mL/min) and preparative (20 mL/min) Waters HPLC system using a
5% to 100% linear gradient of 0.1% TFA in acetonitrile in 0.1% TFA in water over 40
min, followed by 100% 0.1% TFA in acetonitrile over 10 min. HPLC traces were
detected at 215 nm (UV). All desired fractions were collected, concentrated, and
lyophilized. The molecular weights of the α-AApeptides were obtained on a Bruker
AutoFlex MALDI-TOF mass spectrometer using α-cyano-4-hydroxy-cinnamic acid
matrix.31

1.2.6 Antimicrobial assays
Antimicrobial assays were carried out by other members of our lab, according to
the following methods, as reported in our previously published work31:
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"The microbial organisms used were E. coli (JM109), B. subtilis (BR151), multidrug resistant S. epidermidis (RP62A), C. albicans (ATCC 10231), Vancomycin-resistant
E. faecalis (ATCC 700802), Methicillin-resistant S. aureus (ATCC 33592), K.
pneumoniae (ATCC 13383), multi-drug resistant P. aeruginosa ATCC 27853. The
minimum inhibitory concentration (MIC) is the lowest concentration that completely
inhibits the growth of bacteria in 24 h.
The highest concentration tested for antimicrobial activity was 50 µg/mL. The
antimicrobial activities of the lipidated α-AApeptides were determined in sterile 96 -well
plates by broth micro-dilution method. Bacterial cells 2, 4, 5 and fungi 2, 4, 6 were grown
overnight at 37 ºC in 5 mL medium, after which a bacterial suspension (approximately
106 CFU/mL) or fungal suspension Candida albicans (ATCC 10231) (approximately 103
CFU/mL) in Luria broth or trypticase soy was prepared. Aliquots of 50 µL bacterial or
fungal suspension were added to 50 µL of medium containing the α-AApeptides for a
total volume of 100 µL in each well.
The α-AApeptides were prepared in PBS buffer in 2-fold serial dilutions, with the
final concentration range of 0.5 to 50 µg/mL. Plates were then incubated at 37 ºC for 24 h
(for bacteria) or 48 h (for Candida albicans (ATCC 10231). The lowest concentration at
which complete inhibition of bacterial growth (determined by a lack of turbidity) is
observed throughout the incubation time is defined as the minimum inhibitory
concentration (MIC). The experiments were carried out independently three times in
duplicates." 31
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1.2.7 Hemolysis assay
The hemolysis assay was carried out by other members of my research group,
according to the following method, as reported in our previously published paper31:
"Freshly drawn human red blood cells (hRBCs) with additive K2 EDTA (spraydried) were washed with PBS buffer several times and centrifuged at 1000 g for 10 min
until a clear supernatant was observed. The hRBCs were resuspended in 1X PBS to get a
5% v/v suspension. Two fold serial dilutions of α-AApeptides dissolved in 1X PBS from
250µg/ml through 1.56µg/ml were added to a sterile 96-well plate to make up a total
volume of 50 µL in each well. Then 50 µL of 5%v/v hRBC solution was added to make
up a total volume of 100 µL in each well. The 0% hemolysis point and 100% hemolysis
point were determined in 1X PBS and 0.2% Triton-X-100 respectively60. The plate was
then incubated at 37°C for 1hr and centrifuged at 3500rpm for 10 min. The supernatant
(30 µL) was diluted with 100 µL of 1X PBS and hemoglobin was detected by measuring
the optical density at 360nm by Biotek microtiter plate reader (Type: Synergy HT)." 31

1.3 Results and Discussion
1.3.1 Synthesis and characterization
Confirmation of the synthesis of NA-75, 77, and 63 was provided by MALDITOF, shown in Table 1, below.

Table 1: MALDI-TOF mass spectrometry analysis of α-AApeptides
α-AApeptide
NA-63
NA-75
NA-77

Formula
C62H71N7O7
C44H87N7O5
C50H83N7O5

Mass calculated
1025.54
793.68
861.65
22

Mass found
1049.422 (M+Na)+
795.851 (M+H)+
863.739 (M+H)+

Figure 13: Structures of synthesized α-AApeptides.

NA-75 and NA-77 were synthesized by the standard method of α-AApeptide
synthesis previously reported by our laboratory 31, with the additional conjugation to a
16-carbon, saturated fatty acid (palmitic acid) on the amino terminus prior to cleavage
from the resin. Synthesis of the desired compounds was confirmed by MALDI-TOF MS
(mass spectrometry), shown in Table 1.
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NA-63 was made by the alternative, alloc/Fmoc α-AApeptide building block
method, described in detail in Section 1.2.4. During solid phase synthesis, after each
building unit was added to the chain, the Fmoc-protected backbone nitrogen was deprotected and acylated with hydrocinnamic acid. This method was successful in
producing the tri-block sequence NA-63, as confirmed by MALDI-TOF MS, shown in
Table 1. NA-63, a tri-block sequence is analogous to a hexapeptide, since it has six sidechains on the backbone. Although no further investigation of NA-63 was done, the
successful synthesis serves as a proof-of-concept of this synthetic method. It is important
to point out that by using this method, a much greater variety of AApeptide sequences
can be made with fewer building blocks needing to be prepared first, since half of the
side-chains may be selected during the solid phase synthesis. This method may be a
viable strategy to improve the efficiency of synthesis in the future – currently, γAApeptides are being made by a very similar method.44 Another enhancement made
possible by this method is the combining of Fmoc-deprotection and acylation steps of
more than one adjacent building unit, to add the same R-acyl group to each unit. This can
reduce the overall time required for synthesis, when adjacent R-acyl groups are repeated.

1.3.2 Antimicrobial and hemolytic activity
NA-75 and 77 showed potent activity against Gram-positive bacteria, with very
low hemolytic activity. Activity against Gram-negative bacteria, however, was much
lower. Also shown (Figure 14) is the structure and performance of some other lipo-αAApeptides made by other members of my laboratory, for comparison.31 Longer, but
otherwise similar sequences, such as NB-119-1 and NB-119-2, show higher activity
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Table 2: Antimicrobial and Hemolytic Activity.31

Organism
Gram-positive
B. subtilis
S. epidermis
(MRSE)
E. faecalis
(VREF)
S. aureus
(MRSA)
Gram-negative
E. coli
K. pneumonia
P. aeruginosa
Fungus
C. albicans
Hemolysis
(H10/H50)

NA-75

NA-77

NB-1191

MIC (μg/ml)
NBNB-119127
2

NB-1193

NB-123

Pexiganan

2
10

4
15

2
8

2
20

4
10

2
4

4
10

4
8

1

3

4

10

4

4

20

32

5

8

4

8

8

4

8

16

>50
>50
>50

>50
>50
>50

8
>50
20

>50
>50
>50

4
8
12

30
8
8

4
20
10

8
8
8-16

2
>500/>500

2
>500/>500

3
50/300

>50
15/150

4
20/250

20
40/400

10
100/>500

124
181/495

35,49,61,62

against Gram-negative bacteria, while retaining activity against Gram-positive bacteria. It
is interesting that NB-119-1 is only hydrophobic/cationic building block longer than NADespite the reduced bactericidal activity against Gram-negative bacteria, NA-75 and 77,
performed especially well against Gram-positive bacteria and C. albicans, compared not
only to the other lipo-AApeptides, but also to the previously reported unlipidated
AApeptides. Although the benefits of highly broad-spectrum activity are obvious, there
may also be advantages to improving the selectivity between different types of bacteria as
well. Therefore the finding that shorter, lipidated AMP mimetics have improved activity
against Gram-positive bacteria, and reduced activity against Gram-negative may be
useful for guiding the tuning of future AMP mimetic development for optimal activity
against different pathogens.
NA-75 and 77, as well as the longer lipo-α-AApeptides, are expected to make a
more extended structure in aqueous solution, rather than a helical structure typical of
AMPs, with more conformational flexibility, which may actually assist with bacterial cell
25

Pexiganan

Figure 14: Structures of assayed compounds.31
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membrane penetration. Helical structure has been shown not to be necessary for activity,
and might cause higher hemolytic activity.40,53,54 Some AMPs, such as indolicidin, adopt
extended/linear structures rather than helical configurations.47 This conformational
flexibility may be one of the reasons behind the potent activity of NA-75 and NA-77, and
the other lipo-AApeptides.31
Also, in addition to hydrophobic residues on the AApeptide backbone, a lipid tail
was introduced on the N-terminus of the AApeptide oligomer. The lipid tail may
contribute to the ability of such peptides to interact with the bacterial membrane. The
hydrophobic, aliphatic characteristics of the lipid tail may be very beneficial to the
proposed membrane disruption mechanism. Compared to previously reported unlipidated
antimicrobial AApeptides,5,30,31,41 NA-75 and 77 performed especially well against Grampositive bacteria, and C. albicans. In previous work5,41, the shorter 1-3-block sequences,
with similar side-chains to NA-77, had very poor antimicrobial activity, with activity
drastically increased by increasing the length to 5 or 6 blocks. NA-77 is only a 2-block
(tetrapeptide mimetic) sequence, but the addition of a lipid tail results in drastically
improved activity (>5-fold), at least against Gram-positive bacteria. 5,30,31,41
The potent activity of NA-75 and 77 and the other lipo-α-AApeptides against C.
albicans is an indication of the breadth of spectrum that can be obtained by AMPinspired antimicrobials. Activity against C. albicans is significant, because it is a
common fungal pathogen. This demonstrates the broad range of microbes AMP mimetics
can have activity against.
It is important to note that NA-75 and 77 had quite good activity against strains
of S. aureus, S. epidermidis, and E. faecalis, which are multi-drug resistant. MRSA,

27

MRSE, and VREF, respectively, are each resistant to multiple conventional antibiotics,
making infections difficult to treat.63 As these pathogens become increasingly common,
there is an urgent need for the development of antimicrobials which are able to act by
means which are unlikely to cause the development of resistance.63 This is needed both to
treat infections by current drug-resistant bacteria and to prevent the development of
resistance by new microbes.63
Compared to the positive control, pexiganan, the lipo-α-AApeptides performed
very competitively. This is significant because it demonstrates that the lipo-α-AApeptide
AMP mimetics can have activity competitive with, or better than a current drug
candidate.61 This is an indication that further tuning of the AApeptides could yield
clinically useful therapeutic antimicrobials.31
Despite the high antimicrobial activity of NA-75 and 77, they have very low
hemolytic activity. This selectivity is likely due to interactions between the anionic
bacterial membranes, and the basic amino groups of the side-chains, which, in aqueous
solution, are protonated, and, thus, cationic.41 It is thought that this attraction is what
affords AMPs their activity and selectivity, and the charge-charge interactions between
cationic residues and the membrane is a key initial step, preceding hydrophobic
interactions which ultimately damage the membranes, leading to microbial death.30
Mammalian cell membranes, which are typically zwitterionic, would not have these
attractive charge-charge interactions, and would not be as susceptible to this mode of
membrane damage.5
Evidence supporting a membrane-disruption mechanism of microbial cell death
by lipo-α-AApeptides is provided in our published work,30 in which a representative lipo-
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α-AApeptide, NB-119-2, which had potent activity against both Gram-positive and
Gram-negative bacteria, was studied by fluorescence microscopy. It was found to result
in increased uptake of propidium iodide dye, after treatment of E. coli and B. subtilis with
NB-119-2, indicating significant damage to the membrane. The aggregation of dead or
injured cells was also observed, indicative of a loss of membrane potential.30,31 Although
fluorescence microscopy studies were not undertaken for NA-75 and NA-77, it is likely
that they act by a similar mechanism of action.

1.4 Conclusion and Future Work
In conclusion, two lipo-α-AApeptides were identified as having potent
antimicrobial activity, especially to Gram-positive bacteria, with very powerful activity
against three strains resistant to conventional antibiotics – MRSE, VREF, and MRSA.
Others in my laboratory have concurrently synthesized other AApeptide AMP
mimetics, including alpha, gamma, cyclic, and lipidated variations of
AApeptides.5,30,31,41,64 Many of these have good antimicrobial activity, comparable to
pexiganan, currently a drug candidate, with low propensity to cause drug resistance to
develop, high selectivity, and stability to proteolytic degradation. AApeptides may
provide valuable insights into the development of future antibiotics. There is a great, and
urgent need for new antibiotics effective against resistant, virulent bacterial strains. This
need is expected to become more severe in the future.35,47-49
Synthesis of NA-63 from alloc/Fmoc building blocks demonstrates a novel
synthetic method for making α-AApeptides. This method may provide greater variety and
tunability from a relatively small number of building blocks compared to previously
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established methods.44 It is envisioned that interesting peptides may serve as drug leads
for the development of AApeptide analogues, but further study of their secondary
structure characteristics is still required in order to improve the predictability and enhance
more specific interactions. Synthesis of large libraries of AApeptides for further study is
also needed in order to fully realize the potential of these non-natural peptidomimetic
oligomers.44
This and other work has shown that making peptidomimetic analogues of
biologically interesting or potentially useful peptides is one strategy toward modifying
their structures in order to make them better potential therapeutics. AApeptides have been
developed with potent antimicrobial activity and selectivity while being resistant to
proteolytic degradation, and by a mechanism of action which is less likely to lead to
antimicrobial resistance. In this and other work, we have shown that rationally designed,
bio-inspired AApeptides can have interesting, potent, biomimetic activity. More research
needs to be done to enhance the understanding of AApeptide structure and function, in
order to further the development of AApeptide-based chemical probes, potential
therapeutics, and other bio-interesting compounds.
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Chapter 2:
Design and Synthesis of AApeptides for Biomineralization and Self-Assembly to
Form Nanostructures

2.1 Introduction
2.1.1 Overview
Molecular self-assembly is ubiquitous and vitally important to natural biological
systems. Monomeric units are able to self-assemble through non-covalent interactions to
form complex systems, capable of countless unique biological functions.65 Hierarchical
assembly occurring in nature is exhibited by such vitally important biological
components as lipids, proteins, and nucleic acids.66 Understanding molecular selfassembly is very important to the construction of novel or useful nanostructures and
nanomaterials.67 Peptide-based nanomaterials are currently being explored for
applications to nanotechnology, nanomedicine, etc.67 In aqueous solutions, peptide
amphiphiles have been used to generate self-assembled nanostructures,66 forming a
variety of nanostructures, including nanotubes, nanorods, nanovesicles, micelles,
nanobelts, and nanofibers.68-74 Non-natural amphiphilic peptidomimetic oligomers may
potentially lead to new biomimetic nanomaterials with novel functionality. Here, we
report the synthesis of novel amphiphilic peptidomimetics based upon our recently
developed α- and γ-AApeptide scaffolds and their ability to form nanostructures by
molecular self-assembly. As a test of their possible biomimetic applicability, we studied
31

the effect of these compounds on the mineralization of CaCO3 in aqueous solution.
Biomineralization of CaCO3 is an important biological process, and research into CaCO3
mineralization may provide insights into CO2 storage, one possible strategy for
combating global warming.42

Figure 15: α-Peptides, α-AApeptides, and γ-AApeptides. Representative structure of 12-residue αpeptide (top), 6-block α-AApeptide (middle), and 6-block γ-AApeptide (bottom). AApeptides have the
same number of side-chains and amide bonds as α-peptides of the same length.

Herein we report the novel synthesis of several AApeptides, and subsequent
investigation of their potential utility. AApeptides are a new class of peptide mimics
developed by our laboratory, derived from the alpha-chiral PNA (peptide-nucleic acid)
backbone, shown in Figure 4.3 AApeptides are oligomers of N-acylated-N-aminoethyl
amino acids, first reported by members of my research group in 2011.3,4 Our laboratory
reported the first synthesis of both α-AApeptides and γ-AApeptides, which are very
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similar, but differ in the positioning of side-chains along the backbone. α-AApeptides are
discussed in greater detail in Chapter 1 of this manuscript. γ-AApeptides differ from αAApeptides in that the amino acid-derived side chain is at the γ position of each building
block rather than the α-position. As a result, γ-AApeptides are expected to have greater
conformational freedom.4

2.1.2 Self-assembly of peptide amphiphiles
Molecular self-assembly is a natural process which vitally important to, and
universal among organisms of all types. Noncovalent interactions between molecules
allow them to self-assemble, forming complex systems from simple monomeric
subunits.65 A very relevant example of such self-assembled structures in nature is the
lipid membrane, which encloses every cell and is a structure vital to all organisms. This
type of hierarchical self-assembly is also exhibited by proteins and nucleic acids.66
Understanding the mechanisms of biomolecular self-assemble is important for the
advancement of nanotechnology research, such as the development of novel
nanostructures and nanomaterials.67 By elucidating mechanisms of molecular selfassembly, new monomeric subunits may be developed, yielding novel nanomaterials with
new and interesting functionality. Peptide amphiphiles have been of interest in bioorganic
and chemical biology, and have been used to form nanostructures in aqueous solution.
Typically, peptide amphiphiles are composed of a hydrophilic "head" region, and a
hydrophobic "tail" region.75 The hydrophilic region typically consists of charged or polar
amino acids, while the hydrophobic region may contain alkyl chains, lipids, or
hydrophobic amino acids. Peptide amphiphiles have been shown to form a wide array of
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nanostructures, including membranes, micelles, vesicles, nanorods, nanofibers,
nanotubes, and nanobelts.68-74
Biocompatible nanostructures formed by self-assembly of short peptide
amphiphiles may find utility in drug delivery or regenerative medicine.75 Some peptide
amphiphiles have been used as scaffolds for biomineralization of hydroxyapatite, which
may further research into enamel and bone regeneration.75,76 In addition to influencing
biomineralization, peptide-based nanostructures may be useful for drug delivery. One
approach to drug delivery is the sequestration of drug molecules in liposomes or similar
amphiphilic nanoparticles, which would then release the drug molecules some time after
administration.75 Of especially great interest in pharmacology is targeted/triggered drug
delivery, in which drug molecules are only released at a target area of the body.75 This
may be accomplished in self-assembled nanostructures by designing monomers which
disassemble under certain conditions. Such nanostructures would retain the drug
molecules until encountering some stimulus which causes the structure to disassemble,
releasing the drug molecules into solution. Hydrophobic drug molecules may be
especially amenable to this, since they could simply be retained in the hydrophobic inner
region of the nanostructure.
pH plays an important role in the self-assembly of peptide amphiphiles in aqueous
environment. The hydrophilic region of peptide amphiphiles often contains basic or
acidic residues such as lysine or arginine (basic) or aspartic or glutamic acid (acidic). Due
to these basic or acidic groups, self-assembly may be affected by pH. For example, a
peptide amphiphile reported by Stupp, et al, containing a number of acid groups and a
lipid tail, was able to self-assemble only under low pH (<4).76 Under neutral
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(physiological) pH, the peptide amphiphile would not be stable, and, therefore,
ineffective as a means of drug delivery. Peptide-based amphiphiles which self-assemble
at physiological pH but disassemble at high or low pH, however, may be capable of drug
delivery triggered by pH.77

2.1.3 Biomineralization using peptides/peptidomimetics
Biomineralization is important biological process occurring in a wide variety of
organisms, in which peptides and proteins play a very significant role. Biomineralization
is the process by which organisms produce minerals, for a variety of functions. The most
common types of biominerals are calcium salts, especially those of phosphate and
carbonate.78-81 Organisms are able to produce complex structures from the nanometer to
macroscopic level, with precise control of morphology.80,81 Peptides play an important
role in the formation of structures made from the biomineralization of calcite, calcium
phosphates, silicates, and other biominerals. Biominerals are often used by organisms as
skeletons, for structural support, such as hydroxyapatite in bones and teeth, or silica of
the cell walls of diatoms.80,81 The long-extinct trilobites even possessed complex,
compound eyes with lenses made of transparent calcite.82 Other organisms, including
some bacteria and animals, produce magnetite, an iron mineral which allows
magnetoception, the ability to sense magnetic fields.83
Materials or compounds capable of controlling, directing, or catalyzing
mineralization could have many potential uses. One very important potential use is the
mineralization of CaCO3, especially from atmospheric/gaseous CO2, since it is a
"greenhouse" gas, and global warming is an increasingly significant issue. CO2
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capture/storage strategies are currently being explored for combating global warming.
One way of potentially reducing the amount of CO2 in the atmosphere might be by first
hydrating it to convert it to carbonic acid, then forming a solid salt or mineral, which
could then be stored indefinitely. Catalysts of mineral formation from CO32- and various
cations (Ca2- in the case of CaCO3) in aqueous solution are desirable, to give control over
the rate of crystallization, as well as influence over the morphology, size, etc.80,81 Fine
control over mineral morphology may be interesting for nanomaterials research. CaCO3
is also an interesting biomineral in its own right, forming shells of marine organisms, and
many other important biological structures.84
Hydroxyapatite is an especially important biomineral to humans, since it is what
teeth and bones are primarily composed of (>50%).85 Stupp, et al used peptide
amphiphile nanofibers to show that hydroxyapatite mineralization can take place on a
self-assembled nanofiber displaying anionic carboxylate and phosphate groups. They
proposed that mineralization may be induced by local ion supersaturation near the surface
of the nanofibers, facilitated by the presence of carboxylate and phosphate groups in the
hydrophilic region of the peptide amphiphiles.76 They found that the crystallographic caxes of the hydroxyapatite crystals were oriented aligned with the long axes of the
nanofibers, indicating that some kind of templating occurred during mineralization. This
type of biomimetic control of hydroxyapatite mineralization on non-natural amphiphilic
nanostructures is interesting in biomedical research into bone or enamel regeneration.75
Although both peptides and peptidomimetics have been studied as potentially
promoting bone mineral formation by promoting activity of osteoblasts,86 the study of the
direct promotion of mineralization by peptidomimetics is rarely reported.87 Amphiphilic
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peptoids have been developed by Chen, et al, which are able to dramatically affect
mineralization of calcium carbonate, both by altering the morphology of the calcite
crystals, as well as by accelerating crystal growth, even at very low (<50nM)
concentrations.87 This is despite the lack of any apparent formation of self-assembled
structures in solution. The group proposed several mechanism of accelerated crystal
growth. The first is essentially the same mechanism proposed by Stupp, et al 76 –
supersaturation by increasing the local concentration of Ca2+ ions near the peptoids. The
other mechanisms suggested involve reducing the activation barrier for crystal formation,
either through interactions between the peptoids and ions, or through disruption of
interaction of water on the crystal surface.87
Much of the investigation of oligomeric amphiphiles for biomineralization is so
far focused on L,α-peptides or their immediate derivatives, such as the amphiphilic
peptides and lipopeptides. As discussed previously in Chapter 1, natural α-peptides are
often susceptible to proteolytic degradation and may be immunogenic.33 Therefore, the
development of new peptidomimetics that may have similar ability to influence mineral
growth and morphology is needed.

2.1.4 Design and synthetic strategy
2.1.4a NA-75, 77, and 81
Although the design of AApeptides for AMP mimetic and selfassembly/mineralization efforts are guided by different processes and properties,
amphiphilicity appears to be a key factor for both. NA-75 and 77 were initially
synthesized for study as antimicrobials, as described in Chapter 1, and are short,
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lipidated, amphiphilic, α-AApeptides. Even though NA-75 and 77 were designed as AMP
mimetics, they also possess many of the characteristics of compounds which may selfassemble in aqueous solution or promote biomineralization, so they were also studied in
this project. NA-81 (shown in Figure 19) was also synthesized, according to the same
methodology as NA-75/77. NA-81 and NA-75 and 77 are very similar in overall
structure, with the main difference being that NA-81 is anionic, while NA-75 and 77 are
cationic. The different properties of these compounds may give insight into the
importance of AApeptide charge on their self-assembly and mineralization behavior.
It was reasoned that these amphiphilic AApeptides with lipid "tails" and
hydrophilic "heads" might self-assemble in aqueous solution, driven by the alkyl chains
packing together into the center of micelles or other nanostructures, and the anionic or
cationic groups will remain exposed to the water solution.75,76 These initially formed
nanostructures may then be able to aggregate further to form larger, more complex
nanostructures.
TEM was used to observe any nanostructures formed by self-assembly of the
amphiphilic oligomers. Optical microscopy was used to observe CaCO3 crystals formed
in the presence of the AApeptide amphiphiles.

2.1.4b NA-133, 135, 137, and 139
Four new amphiphilic γ-AApeptides were designed and synthesized in order to
investigate their self-assembly in aqueous media and ability to influence CaCO3
mineralization. The structures of these compounds are given in Figure 16. The new γ-
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Name

Arrangement
of charged
groups

NA-133

+++---

NA-135

+-+-+-

NA-137

++++++

NA-139

------

Structure

Figure 16: NA-133, 135, 137, and 139.

AApeptides were made by the standard building block method, from 2 different γAApeptide building blocks: one derived from phenylalanine/γ-aminobutyric acid, and
one from phenylalanine/succinic acid. Two of the sequences, NA-137 and 139, were each
made from a single repeated building block. NA-133 and 135, however, were made from
an alternating pattern of the two building blocks, as shown below. NA-137 and 139 may
undergo self-assembly in aqueous solution due to hydrophobic/hydrophilic interactions

39

with water. The non-polar phenyl side-chains may aggregate in the center of
nanostructures, while the anionic or cationic side-chains are expected to remain exposed
to the aqueous environment.76 NA- 133 and 135 are expected to behave similarly, but
with additional intermolecular interactions made possible by the alternating
cationic/anionic side-chains. This may allow the formation of nanostructures with
zwitterionic surface charge, rather than overall cationic or anionic, which may have some
desirable effects, especially with regard to the pH at which self-assembly takes place.
TEM was used to observe any nanostructures formed by self-assembly of the
amphiphilic oligomers. Optical microscopy was used to observe CaCO3 crystals formed
in aqueous solution in the presence of the AApeptide amphiphiles.

2.1.4c NA-137+139
Additionally, a 1:1 mixture of NA-137 (all positively charged side-chains) and
NA-139 (all negatively charged side-chains) was prepared, since we believed the
complementary charges of the amino and carboxylate groups might lead to interesting
interactions, giving rise to unique self-assembly or mineralization behavior. Together,
they might show an increased propensity to self-assemble, due to electrostatic interaction
between oppositely charged side chain groups. The 1:1 mixture (referred to herein as NA137+139) was studied by TEM to observe any nanostructures formed. Optical
microscopy was used to observe CaCO3 crystals formed in aqueous solution in the
presence of the mixture.
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2.2 Experimental
2.2.1 γ-AApeptide building block synthesis
Reductive amination of glycine benzyl ester hydrochloride (neutralized with
TEA) was carried out using 1 eq Fmoc-phenylalanine aldehyde, 65,66 2 eq NaCNBH3 and
a catalytic amount of acetic acid. 64,65 Following purification by flash chromatography
using 1:1 hexane:ethyl acetate, the resulting secondary amine was then acid coupled to
succinic acid mono-t-butyl ester (2 eq) using 2 eq DhbtOH (3-hydroxy-1,2,3benzotriazin-4(3H)-one) and 2 eq DIC (N, N’-Diisopropylcarbodiimide) as activation
agents. The final step was hydrogenation, which was carried out in the presence of H2 gas
and 20% palladium on activated carbon as catalyst in methanol. The other building block,
shown in Figure 17 was prepared similarly, but by acylating the secondary amine with
Boc-protected γ-aminobutyric acid instead.

Figure 17: γ-AApeptide building blocks.

2.2.2 Solid phase synthesis of NA-133, 135, 137, and 139
γ-AApeptides were prepared on a Rink amide resin in peptide synthesis vessels on
a Burrell wrist-action shaker following the standard Fmoc chemistry solid phase peptide
41

Figure 18: Synthetic scheme of NA-133.
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synthesis protocol using the previously (Section 2.2.1) synthesized γ-AApeptide building
blocks (shown in Figure 17).3,4,42,47-49
Each coupling cycle comprised of Fmoc deprotection using 20% piperidine in
DMF, and 8 h coupling of 1.5 eq γ-AApeptide building blocks onto resin using 4 eq DIC
(diisopropylcarbodiimide)/DhbtOH (3-4-Dihydro-3-hydroxy-4-oxo-1-2-3-benzotriazine)
in DMF. The solid support was then transferred to a 4 mL vial and the γ-AApeptides
were cleaved from resin by 74:24:2 TFA/CH2Cl2 /triisopropylsilane for 2 hours.4,88

2.2.3 Solid phase synthesis of NA-75, 77, and 81
Lipidated α-AApeptides were prepared on Rink amide resin in peptide synthesis
vessels on a Burrell wrist-action shaker following the standard Fmoc chemistry solid
phase peptide synthesis protocol using the previously (Section 1.2.1) synthesized αAApeptide building blocks. 3,4,42,47-49
Each coupling cycle consisted of Fmoc deprotection using 20% piperidine in
DMF, followed by 8 h coupling of 1.5 eq α-AApeptide building blocks onto the resin
using 4 eq DIC (diisopropylcarbodiimide) and 4 eq DhbtOH (3-4-Dihydro-3-hydroxy-4oxo-1-2-3-benzotriazine) in DMF. Lipidation was achieved on resin by capping the Nterminus of the final α-AApeptide building block using palmitic acid (C16). The dried
solid support was then transferred into a 4 mL vial and the lipidated α-AApeptides were
cleaved from the resin by 50:48:2 solution of TFA/CH2Cl2 /triisopropylsilane
overnight.3,4,31,42,47-49
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2.2.4 Purification and characterization α- and γ-AApeptides
Following cleavage of AApeptides from solid support, the solvent was evaporated
by rotary evaporation and the residues were analyzed and purified on an analytical (1
mL/min) and preparative (20 mL/min) Waters HPLC system using a 5% to 100% linear
gradient of 0.1% TFA in acetonitrile in 0.1% TFA in water over 40 min, followed by
100% 0.1% TFA in acetonitrile over 10 min. HPLC traces were detected at 215 nm (UV).
All desired fractions were collected, concentrated, and lyophilized. The molecular
weights of the AApeptides were obtained on a Bruker AutoFlex MALDI-TOF mass
spectrometer using α-cyano-4-hydroxy-cinnamic acid matrix.3,4,30,31

2.2.5 TEM studies
Samples were applied to TEM grids by adding 10μL AApeptide solution, and the
grids were allowed to dry for about 1h. After drying, the grids were stained with 10μL of
1% (w/w) uranyl acetate/water solution, and extra solution was removed by immersion
using wetfilter paper after 30s. The grids were allowed to dry prior to TEM study. TEM
images were obtained on a FEI Morgagni 268D TEM with an Olympus MegaView III
camera on the microscope. The microscope uses AnalySiS software to run the camera
and was operated at 60 kV.42

2.2.6 CaCO3 mineralization studies
(NH4)2CO3 vapor was diffused over a 96-well plate, in which other wells
contained 198μL of 5.0 mM CaCl2 solution and 2μL of 1 mg/mL AApeptide, giving a
final concentration of 10μg/mL. The control did not contain AApeptide; instead, 2 μL of
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water was added. The 96-well plate was placed in a closed Ziploc bag for ~ 24 hours to
allow (NH4)2CO3 vapor diffusion. The morphology of crystals was investigated by
optical microscopy.42,87

2.3 Results and Discussion
2.3.1 Synthesis and characterization
Confirmation of the synthesis of the AApeptides was provided by MALDI-TOF,
found in Table 3, below.

Table 3: MALDI-TOF mass spectrometry analysis of AApeptides.
AApeptide
NA-75
NA-77
NA-81
NA-133
NA-135
NA-137
NA-139

Formula
C44H87N7O5
C50H83N7O5
C38H69N5O9
C90H120N16O18
C90H120N16O18
C90H129N19O12
C90H111N13O24

Mass calculated
793.68
861.65
739.51
1712.90
1712.90
1668.01
1757.79

Mass found
795.851 (M+H)+
863.739 (M+H)+
763.646 (M+Na)+
1714.071 (M+H)+
1714.089 (M+H)+
1670.099 (M+H)+
1780.882 (M+Na)+

NA-75, 77, and 81 were synthesized by the standard method of α-AApeptide
synthesis previously reported by our laboratory,3 and discussed in Chapter 1, with the
additional conjugation to a 16-carbon, saturated fatty acid (palmitic acid) on the amino
terminus prior to cleavage from the resin.31 NA-133, 135, 137, and 139 were prepared by
the standard γ-AApeptide synthesis previously reported by our laboratory.4 Synthesis of
the desired compounds was confirmed by MALDI-TOF MS, shown in Table 3.
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NA-75

NA-77

NA-81

NA-133

NA-135

NA-137

NA-139

Figure 19: Structures of synthesized α-AApeptides.

46

2.3.2 TEM studies of self-assembly by AApeptide amphiphiles

Figure 20: TEM of NA-133.

Figure 21: TEM of NA-135.
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Figure 21 (Cont.): TEM of NA-135.

Figure 22: TEM of NA-137.

Figure 23: TEM of NA-137+139.
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Figure 23 (Cont.): TEM of NA-137+139.

TEM of the AApeptide amphiphiles are shown in the figures above. No
nanostructures formed from NA-75, 77, 81, or NA-139 were observed by TEM, but the γAApeptide amphiphiles NA-133, 135, 137, and the mixture NA-137+139 clearly formed
some interesting nanostructures. NA-133 and 135 formed small (< 50nm) nanoparticles.
The mixture NA-137+139 formed large nanorods. Several of the TEM images of NA137+139 show what may be smaller nanostructures aggregating to form the larger
nanorods, hinting at a hierarchical mechanism of self-assembly. The TEM images of NA137 are not as clearly defined, but they may show small nanoparticles or nanofibers.
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It is important to note that these nanostructures were formed at pH 7. Many
peptide amphiphiles are generally anionic or cationic and self-assemble only at high or
low pH. Purely anionic amphiphiles often only form stable nanostructures under low
pH76, but disassemble at neutral (physiological), or basic pH. The nanostructures of the
zwitterionic NA-133, 135, and 137+139 are formed at neutral or near-neutral pH. It may
be possible to further develop such AApeptide amphiphiles tuned to form stable
zwitterionic nanostructures at neutral pH, but break down into their subunits under acidic
or basic conditions. Nanostructures which can be tuned to disassemble under certain
conditions are of great interest to chemical biology, because they may be useful for
stimulus-triggered drug delivery, if drug molecules can be introduced into the
hydrophobic inner region of the nanostructure.67
The hydrophobicity imparted by the phenylalanine-derived side-chains appears to
be capable of sufficiently driving aggregation of the AApeptides in aqueous conditions.
Charge-charge interactions between the zwitterionic γ-AApeptides may also help to
stabilize the aggregation (at least at neutral pH).
This is supported by our observation that the zwitterionic γ-AApeptides NA-133
and 135, as well as the complementarily-charged mixture of NA-137+139, have a higher
propensity to form defined nanostructures than the fully anionic or cationic counterparts
alone.

2.3.3 Calcium carbonate mineralization
Calcium carbonate mineralization was done by diffusion of CO2 vapor from
ammonium carbonate, into aqueous solution containing CaCl2 and AApeptide (control
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had water instead of AApeptide.) There were no subjective differences in the overall
number or size of the CaCO3 crystals detectable by visual microscopy between the
AApeptides and each other or the control (H2O solution). The rhombohedral crystals
typical of calcite are visible in the control sample. CaCO3 crystals grown in the presence
of many of the AApeptides appear to aggregate together, forming clusters of CaCO3
crystals. The morphology of the CaCO3 crystals grown in the presence of AApeptides

Figure 24: CaCO3 mineralization control.

Figure 25: CaCO3 mineralization of NA-75.
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Figure 25 (Cont.): CaCO3 mineralization of NA-75.

Figure 26: CaCO3 mineralization of NA-77.
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Figure 27: CaCO3 mineralization of NA-81.

Figure 28: CaCO3 mineralization of NA-133.
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Figure 29: CaCO3 mineralization of NA-135.

Figure 30: CaCO3 mineralization of NA-137.
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Figure 31: CaCO3 mineralization of NA-139.

Figure 32: CaCO3 mineralization of NA-137+139.
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Figure 32 (Cont.): CaCO3 mineralization of NA-137+139.

were markedly different from the rhombohedral crystals of the control. NA-75 resulted in
spherical CaCO3 crystals, which aggregate together. NA-77 and several others resulted in
irregularly shaped structures. Clearly, the AApeptide amphiphiles are able to have a
significant impact on the morphology of the calcium carbonate crystals.
Nanostructures formed from AApeptides which are negatively charged at pH 7
would be expected to induce CaCO3 mineralization by similar mechanisms to anionic
peptide amphiphiles – nucleating crystal formation by local supersaturation of ions.76
Cationic or zwitterionic AApeptides also influence CaCO3 mineralization, perhaps
through a similar ion supersaturation mechanism. While anionic sequences may cause
supersaturation of Ca2+ ions, cationic sequences could similarly cause supersaturation of
their counter-ion, leading to mineral nucleation. Zwitterionic nanostructures, such as
those formed by NA-137+139, present another interesting possibility – a mechanism by
which both cations and anions are templated by the anionic and cationic residues at the
surface nanostructures.75,76 While few of the AApeptide amphiphiles formed
nanostructures, nearly all of them had some influence on CaCO3 crystal morphology. It is
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therefore impossible to draw any firm conclusions about the effects of nanostructure
morphology on CaCO3 mineralization without further study.

2.4 Conclusion and Future Work
We have demonstrated the ability of rationally designed, bio-inspired, novel
AApeptide amphiphiles to form nanostructures by molecular self-assembly. Several γAApeptides, NA-133, 135, and a 1:1 ratio of NA-137 and 139 were observed to form
nanostructures in aqueous solution. NA-137+139 formed large nanorods, and NA-133
and 135 formed spherical nanoparticles, possibly micelles or liposomes.
Furthermore, we have demonstrated the ability of these and other AApeptide
amphiphiles to influence CaCO3 mineralization. CaCO3 crystals formed in the presence
of a number of AApeptide amphiphiles were found to have different morphology than
typical rhombohedral calcite crystals. This finding is significant to the development of
novel peptide-based nanomaterials to undergo mineralization of biologically relevant
minerals. The ability for the AApeptides to influence CaCO3 mineralization may also be
relevant to research into CO2 capture and storage, since the source of carbonate for the
mineralization was gaseous CO2, diffused over the aqueous solution. This is an important
area of research, because sequestration of atmospheric CO2 is one strategy to alleviate
global warming.87
The properties of AApeptide amphiphiles and their nanostructures still require
further study. Study of the nanostructures to investigate their possible utility for triggered
drug delivery would also be interesting, since there is a need for tunable, biodegradable,
vehicles for drug delivery.87 Kinetic study of CaCO3 mineralization in the presence of our
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AApeptide amphiphiles to determine whether the rate of CaCO3 mineralization can be
improved by such systems is also needed.87 Also of interest is hydroxyapatite
biomineralization, which may be important to research into bone or enamel
regeneration.75,76
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